Zevra Therapeutics Inc (NASDAQ: ZVRA) open the trading on Thursday, with great promise as it jumped 1.42% to $7.15, before settling in for the price of $7.05 at the close. Taking a more long-term approach, ZVRA posted a 52-week range of $4.20-$9.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 42.16%. Meanwhile, its Annual Earning per share during the time was 29.64%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 80.77%. This publicly-traded company’s shares outstanding now amounts to $53.67 million, simultaneously with a float of $53.53 million. The organization now has a market capitalization sitting at $386.93 million. At the time of writing, stock’s 50-day Moving Average stood at $7.64, while the 200-day Moving Average is $7.71.
Zevra Therapeutics Inc (ZVRA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Zevra Therapeutics Inc’s current insider ownership accounts for 1.08%, in contrast to 62.90% institutional ownership. According to the most recent insider trade that took place on Mar 28 ’25, this organization’s Director bought 300 shares at the rate of 7.84, making the entire transaction reach 2,352 in total value, affecting insider ownership by 1,800. Preceding that transaction, on Mar 19 ’25, Company’s Director bought 10,000 for 7.96, making the whole transaction’s value amount to 79,624. This particular insider is now the holder of 40,000 in total.
Zevra Therapeutics Inc (ZVRA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.54 per share during the current fiscal year.
Zevra Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 80.77% and is forecasted to reach 0.65 in the upcoming year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Let’s observe the current performance indicators for Zevra Therapeutics Inc (ZVRA). It’s Quick Ratio in the last reported quarter now stands at 2.47. The Stock has managed to achieve an average true range (ATR) of 0.43. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 16.39.
In the same vein, ZVRA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.23, a figure that is expected to reach -0.18 in the next quarter, and analysts are predicting that it will be 0.65 at the market close of one year from today.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
[Zevra Therapeutics Inc, ZVRA] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 68.88% While, its Average True Range was 0.44.
Raw Stochastic average of Zevra Therapeutics Inc (ZVRA) in the period of the previous 100 days is set at 26.89%, which indicates a major fall in contrast to 61.74% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 58.31% that was higher than 44.73% volatility it exhibited in the past 100-days period.
